Biogen announced almost one year ago that it would undergo a search to replace Vounatsos, ultimately landing on Viehbacher, the former Sanofi chief, to take his place.
Bradway wasn’t the only Amgen executive who was well-compensated last year.
The holding company’s resurgence has resulted in a near-doubling of Read’s compensation.
The effort is expected to deliver annualized future cost savings of $4.3 million to Evofem.
Moderna noted in its report that the ratio of Bancel’s total compensation to a median employee’s total compensation is 119 to 1.
In addition to Duato, J&J executives have been well compensated, though the pay has been scaled back compared to previous years.
Walmsley, who has been CEO of GSK since 2017, received a total fixed pay of £1.6 million and £6.8 in total pay for performance.
Despite AbbVie’s solid performance, executive compensation continues to be a contentious industry issue.
Get the most out of
Register for free and enjoy unlimited access to: